| Literature DB >> 35095697 |
Shuxian Chen1, Jinglong Yu2, Qiang Zhang2, Jin Zhang3, Ying Zhang4, Junhong Wang2.
Abstract
Objective: Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by developmentally inappropriate inattention, hyperactivity, and impulsivity. Multiple cognitive training appeared to be more effective than working memory training, but the evidence remains insufficient, particularly for the subgroup symptoms and executive function behaviors at home. Further analysis of the impact of factors on the effectiveness would facilitate the development of cognitive training.Entities:
Keywords: attention deficit disorder with hyperactivity; children; cognitive training; executive function (EF); meta-analysis
Year: 2022 PMID: 35095697 PMCID: PMC8792444 DOI: 10.3389/fpsyg.2021.810298
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
Characteristics of the studies included in the analysis.
| Studies | Training ( | Setting | Age | Medication (%) | Criteria used for diagnostic | Outcomes | Duration (weeks) and sessions | Compliance (%) | Risk of bias |
|
| MCT (8)/Waitlist (13) | School | 12.4 ± 0.9 | 60 | Not given | CRS-R; BRIEF | 16/32 | 93 | H |
|
| WMT (33)/TAU (34) | School | 10.4 ± 0.0.7 | 61 | ICD-10 | ADHD–RS; BRIEF | 7/25 | 97 | H |
|
| Attention (54)/Waitlist (51) | Home | 9.3 ± 1.4 | 68.6 | DSM-4 | SNAP- IV; BRIEF | 8/16 | 97 | H |
|
| WMT (26)/Placebo (21) | Home | 6.5 ± 0.6 | 0 | DSM-IV-TR | ADHD-RS; BRIEF | 5/25 | 85 | H |
|
| WMT (44)/Placebo (41) | Home | 8.4 ± 1.4 | 29.4 | Kiddie-SADS | DBDR | 5/25 | 78 | H |
|
| MCT (34)/Waitlist (36) | School | 8.9 ± 1.0 | 48.6 | DSM-4 | Conners 3-P | 20/40 | 97 | S |
|
| MCT (18)/Waitlist (22) | Home | 9.79 ± 1.04 | 72.5 | DSM-IV | DBDRS; BRIEF | 6/25 | 93 | H |
|
| MCT (10)/Waitlist (9) | Home | 5.0 ± 1.3 | 0 | DSM-5 | SNAP-IV; BRIEF | 8/8 | 76 | H |
|
| MCT (30) Braingame Brian (BGB)/Placebo (30) | Home | 10.6 ± 1.4 | 72.4 | DSM-IV-TR | DBDRS; BRIEF | 5/25 | 95 | L |
|
| WMT (27)/Placebo (27) | Home | 8.79 ± 1.75 | 0 | DSM-IV-TR | BRIEF | 5/25 | 94 | H |
|
| WMT (22)/Placebo (23) | Home | 12.0 ± 1.0 | 65.2 | DSM-IV | ADHD-RS; BRIEF | 5/25 | 94 | H |
|
| MCT (12)/Placebo (11) | Clinic | 7–12 | 17.4 | Not given | SNAP-IV | 8/20 | 100 | H |
|
| MCT (38)/Wait-list (30) | Clinic | 8.3 ± 1.3 | 14.7 | DSM-IV | ADHD-RS; BRIEF | 12/12 | 79 | H |
|
| WMT (18)/TAU (10) | Home | 13.8 ± 0.9 | 100 | DSM-IV | CRS-R | 5/25 | 58 | S |
|
| WMT (17)/Placebo (14) | Home | 7–13 | 54.8 | DSM-5 | Conners 3-P; BRIEF | 6/25 | 60 | S |
|
| MCT (41)/Active knowledge training (39) | Home | 10.14 ± 2.02 | Not given | DSM-IV | CPRS–R; BRIEF | 4/20 | 79 | H |
|
| MCT (50)/Wait (51) | Clinic | 8.5 ± 0.85 | 65.40% | DSM-IV | CPRS–R; BRIEF | 12/12 | 94 | L |
MCT, multiple cognitive training; WMT, working memory training; TAU, treatment as usual; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders (4th ed. text rev); ICD-10, The International Classification of Diseases the Tenth Revision; DSM-V, Diagnostic and Statistical Manual of Mental Disorders (5th ed. DSM-5); DSM-IV, Diagnostic and Statistical Manual of Mental Disorders (4th ed. DSM-IV); Kiddie-SADS, Kiddie Schedule for Affective Disorders and Schizophrenia; CRS-R, Conners’s Rating Scales–Revised; BRIEF, behavioral rating inventory of executive functioning; ADHD–RS, ADHD-Rating Scale; Conners 3-P, Conners-3 Parent; SNAP-IV, Swanson, Nolan, and Pelham DSM-IV, ADHD Rating Scale; DBDRS, Disruptive Behavior Disorder Rating scale; CPRS-R, Connors’ Parent Rating Scale revised.
FIGURE 1PRISMA flow diagram of selection of studies.
FIGURE 2Venn diagram.
Summary of results showing pooled standardized mean differences (SMD) between treatment and control arms for each outcome.
| Outcome | subgroup | evaluator | Study | Effect | Heterogeneity | ||
| SMD | 95%CI |
|
| ||||
| Inattention symptoms | Overall | Clinician- or parent-rated | 15 | –0.390 | –0.675 to –0.104 | 71.4% | 0.000 |
| Only parent-rated | 13 | –0.390 | –0.699 to –0.080 | 73.8% | 0.000 | ||
| Blind | Clinician- or parent-rated | 6 | –0.003 | –0.335 to 0.329 | 46.7% | 0.095 | |
| Attention | Parent-rated | 1 | –1.460 | –1.892 to –1.028 | N | N | |
| WMT | Clinician- or parent-rated | 6 | 0.042 | –0.233 to 0.317 | 28.2% | 0.224 | |
| Only parent-rated | 5 | 0.034 | –0.300 to 0.368 | 42.4% | 0.139 | ||
| MCT | Clinician- or parent-rated | 8 | –0.507 | –0.722 to –0.292 | 0.0% | 0.619 | |
| Only parent-rated | 7 | –0.481 | –0.702 to –0.261 | 0.0% | 0.640 | ||
| Hyperactivity/impulsivity symptoms | Overall | Clinician- or parent-rated | 15 | –0.160 | –0.367 to 0.046 | 46.7% | 0.024 |
| Parent-rated | 13 | –0.190 | –0.400 to 0.020 | 44.5% | 0.042 | ||
| Attention | Parent-rated | 1 | –0.569 | –0.959 to –0.178 | N | N | |
| WMT | Clinician- or parent-rated | 6 | 0.127 | –0.171 to 0.425 | 38.3% | 0.151 | |
| Parent-rated | 5 | 0.061 | –0.271 to 0.392 | 41.5% | 0.144 | ||
| MCT | Clinician- or parent-rated | 8 | –0.305 | –0.518 to –0.093 | 0.0% | 0.588 | |
| Parent-rated | 7 | –0.294 | –0.513 to –0.076 | 0.0% | 0.492 | ||
| GEC of BRIEF | Overall | Parent-rated | 13 | –0.319 | –0.527 to –0.111 | 44.5% | 0.042 |
| Blind | Parent-rated | 5 | 0.052 | –0.252 to 0.356 | 10.7% | 0.345 | |
| Attention | Parent-rated | 1 | –0.821 | –1.219 to –0.422 | N | N | |
| WMT | Parent-rated | 5 | 0.091 | –0.163 to 0.345 | 0.0% | 0.575 | |
| MCT | Parent-rated | 7 | –0.499 | –0.707 to –0.290 | 0.0% | 0.997 | |
| BRI of BRIEF | Overall | Parent-rated | 6 | –0.182 | –0.387 to 0.022 | 0.0% | 0.439 |
| Attention | Parent-rated | 1 | –0.492 | –0.881 to –0.104 | N | N | |
| WMT | Parent-rated | 3 | 0.049 | –0.269 to 0.366 | 0.0% | 0.948 | |
| MCT | Parent-rated | 2 | –0.214 | –0.582 to 0.155 | 0.0% | 0.645 | |
| MI of BRIEF | Overall | Parent-rated | 7 | –0.244 | –0.649 to 0.160 | 76.7% | 0.000 |
| Attention | Parent-rated | 1 | –0.896 | –1.298 to –0.494 | N | N | |
| WMT | Parent-rated | 3 | 0.254 | –0.044 to 0.553 | 0.0% | 0.501 | |
| MCT | Parent-rated | 3 | –0.509 | –0.831 to –0.187 | 0.0% | 0.560 | |
GEC, global executive composite; BRI, behavioral regulation index; MI, metacognition index.
Metaregression analysis based on REML.
| Dependent | Covariates | Number of obs | Exp(b) |
|
| Inattention symptoms | Combination of medication | 14 | 0.996 | 0.522 |
| Duration | 15 | 0.966 | 0.273 | |
| Sessions | 15 | 1.026 | 0.197 | |
| Frequency | 15 | 1.108 | 0.017 | |
| Hyperactivity/impulsivity Symptoms | Combination of medication | 14 | 0.996 | 0.367 |
| Duration | 15 | 0.971 | 0.212 | |
| Sessions | 15 | 1.016 | 0.281 | |
| Frequency | 15 | 1.198 | 0.003 | |
| Global Executive Composite of BRIEF | Combination of medication | 12 | 0.994 | 0.153 |
| Duration | 13 | 0.977 | 0.334 | |
| Sessions | 13 | 1.014 | 0.281 | |
| Frequency | 13 | 1.027 | 0.056 |
Publication bias with Egger’s test.
| Small-study effects of publication bias | Number of studies | Coef |
|
| 95%CI |
| Inattention symptoms | 15 | –1.231 | –0.58 | 0.571 | –5.808 to 3.345 |
| Hyperactivity/impulsivity symptoms | 15 | –0.952 | –0.62 | 0.544 | –4.256 to 2.351 |
| Global executive composite of BRIEF | 13 | 0.558 | 0.33 | 0.745 | –3.126 to 4.241 |